U.S. Hemostats Market – Industry Trends and Forecast to 2031

 U.S. Hemostats Market Analysis and Size

In the hemostats market, advancements transform surgical procedures by providing effective bleeding control. These hemostatic agents cater to diverse medical needs, ensuring rapid and reliable hemostasis. From traditional gauze-based products to advanced biomaterials, innovations offer improved patient outcomes, reduced surgical complications, and enhanced healthcare efficacy.                            

Data Bridge Market Research analyses that the U.S. hemostats market, which was USD 1.18 billion in 2023, is expected to reach USD 2.07 billion by 2031, and is expected to undergo a CAGR of 7.3% during the forecast period of 2024 to 2031. This indicates that the market value. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

U.S. Hemostats Market Scope and Segmentation

Market Definition

Hemostats are medical tools or substances used to control bleeding during surgery or injuries. They work by promoting blood clotting and can be in the form of powders, gels, or absorbable materials. Essential in various medical procedures, hemostats aid in preventing excessive blood loss and promoting faster wound healing.            

U.S. Hemostats Market Dynamics

Drivers

• Increasing Prevalence in  Aging Population Create Demand for Hemostats

The global increase in the elderly demographic is driving up the occurrence of chronic illnesses and surgical interventions. Consequently, there is a heightened necessity for hemostats to effectively address bleeding complications in this demographic. This trend underscores the growing demand for hemostatic agents as a critical component in managing surgical procedures among the aging population.

• Growing Incidence of Trauma Cases Demand for Hemostatic Agents

The rising incidence of trauma injuries, stemming from accidents and emergencies, underscores the critical need for prompt and efficient hemostasis to prevent excessive blood loss. This urgency fuels the demand for hemostatic agents, driving their increasing use in emergency medical settings and trauma surgeries worldwide.​​​​​​​

Opportunities

• Preference for Minimally Invasive Surgeries

The shift towards minimally invasive surgeries fuels demand for hemostats adept at managing bleeding in these procedures. As patients and healthcare providers favor less invasive techniques, there is a growing need for effective hemostatic agents tailored to these settings. This trend propels market growth as hemostats become integral to ensuring successful outcomes in minimally invasive procedures.

• Increasing Awareness about Blood Loss Management

Growing awareness among healthcare professionals about the critical role of effective blood loss management enhances the adoption of hemostatic agents across diverse medical environments. This heightened awareness underscores the significance of promptly controlling bleeding to optimize patient outcomes, driving the increased utilization of hemostatic products in clinical practice. 

Restraints/Challenges

• Risk of Adverse Reactions from Hemostatic Agents

Concerns over adverse reactions such as allergies or thrombosis linked to specific hemostatic agents can hinder market acceptance. Healthcare providers and patients hesitate to use these products due to security fears, potentially leading to reduced sales and market share for affected manufacturers, impacting overall market growth and profitability. 

• Disruptions of Supply Chain Hinder Patient Access

Supply chain disruptions, such as raw material shortages or manufacturing delays, pose significant challenges to the hemostats market by impeding product availability and distribution channels. Transportation issues exacerbate these problems, affecting timely delivery to healthcare facilities. These disruptions can hinder patient access to critical hemostatic products, impacting healthcare delivery and market stability. 

This U.S. hemostats market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the U.S. hemostats market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In May 2022, Precision BioLogic Inc. unveiled its cryocheck Chromogenic Factor IX assay across Canada, the European Union, the U.K., Australia, and New Zealand, enhancing hemostasis diagnostics
• In February 2022, Futura Surgicare Pvt Ltd diversified its offerings with Hemostax Standard, an absorbable hemostat under the new Dolphin Hemostats brand, aiding surgeons in efficient bleeding control
• In July 2021, BD's acquisition of Tepha, Inc. strengthened its expertise in resorbable polymer technology, propelling the advancement of cutting-edge medical products. This development significantly influences the hemostats market by expanding capabilities and contributing to innovative solutions

U.S. Hemostats Market Scope

The U.S. hemostats market is segmented on the basis of type, formulation, application, indication, distribution channel, and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Combination Agent Hemostats
• Thrombin Based Hemostats
• Collagen Based Hemostats
• Oxidized Regenerated Cellulose Based Hemostats
• Gelatine Based Hemostats

 Formulation

• Matrix and Gel Hemostats
• Sheet and Pad Hemostats
• Sponge Hemostats
• Powder Hemostats

 Application

• Orthopedic
• General Surgery
• Neurological Surgery
• Cardiovascular Surgery
• Reconstructive Surgery
• Gynecological Surgery

 Indication

• Wound Closure
• Surgical Hemostats

  Distribution Channel

• Direct Tender
• Third Party Distributors

 End Users

• Hospitals
• Ambulatory Centres
• Community Healthcare
• Clinics
• Others

Healthcare Infrastructure growth Installed base and New Technology Penetration

The U.S. hemostats market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for U.S. hemostats market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the U.S. hemostats market. The data is available for historic period 2016-2021.

Competitive Landscape and U.S. Hemostats Market Share Analysis

The U.S. hemostats market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to U.S. hemostats market.

Some of the major players operating in the U.S. hemostats market are:

• B. Braun SE (Germany)
• Baxter. (U.S.)
• Marine Polymer Technologies, Inc. (U.S.)
• Teleflex Incorporated. (U.S.)
• Ethicon, Inc. (U.S.)
• Pfizer Inc. (U.S.)
• GELITA MEDICAL (Germany)
• Anika Therapeutics, Inc. (U.S.)
•  Stryker (U.S.)
• Integra Lifesciences Corporation (U.S.)
•  Johnson & Johnson Services, Inc. (U.S.)
•  Medtronic (Ireland)
• BD (U.S.)
• Hemostasis, LLC. (U.S.) 

SKU-66350